but for more on this, we're joined now by kevin newton, who is a lawyer in the h. b, a patent lawyer and intellectual property rights law. semi joins us from chicago. thanks very much for being with us here on al jazeera. this will, can you just give us a, an idea of exactly what is at stake here? i mean, is this just the legal wrangling between pharmaceutical johns, which i've already made billions of dollars from the spec, saying, well, true, but they've also invested millions of dollars to get to the vaccine. i think that's probably what they would tell you. it is very much for conventional law patton lawsuit, which as your reporter said, who discovered it 1st to fall in pen application for it 1st. we'll decide who is entitled to the royalties for this. and i'll mention that both companies have said, i mean majority since the plaintiff have said that they're not seeking an injunction to the power low case in the united states. they're not asking anybody to stop making the vaccine. they're just saying how to do a portion the, the value of that. and the reality is